Preying On a Tumor's Weakness with Nanotechnology to Fight Cancer

Winner of this year's $30,000 Lemelson–M.I.T. Student Prize uses gold nanoparticles to kill malignancies but spare healthy tissue















Share on Tumblr

cancer, nanotechnology

GEOFFREY VON MALTZAHN: The 28-year-old PhD candidate has won this year's $30,000 Lemelson–M.I.T. Student Prize for his work developing ways to use nanotechnology to fight cancer. Image: COURTESY OF HARVARD-MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY

The Harvard–M.I.T. Division of Health Sciences and Technology (HST) today named Geoffrey von Maltzahn this year's recipient of the $30,000 Lemelson–M.I.T. Student Prize for developing  a technique that utilizes nanosize gold particles to target malignant tumors and kill cancer cells but spares healthy tissue. Established in 1994, the award is given out annually to a Massachusetts Institute of Technology senior or graduate student who has contributed significantly to the fields of science or technology.

The approach capitalizes on "tumors behaving like tumors," says von Maltzahn, a 28-year-old PhD candidate, which means malignancies trigger the growth of as many new blood vessels as quickly as possible to nourish and make them thrive. But instead of feeding these tumors, von Maltzahn relies on these ultra-porous nascent blood vessels to transport rod-shaped gold nanoparticles (injected into cancer patients) inside tumors, where they latch onto malignant tissue.

Although other researchers have tested the use of nanoparticles to fight cancer (read about another M.I.T.–Harvard effort here), von Maltzahn has developed two ways to attack tumors once the nanoparticles have set up shop there. The first is to shine a near-infrared laser on the patient's skin above the malignancies; the light heats the gold enough to interrupt and destroy cancer cells with minimal, if any, damage to surrounding healthy cells. In preclinical mouse trials a single nanoparticle injection (which includes trillions of nanoparticles) eradicated 100 percent of tumors when combined with near-infrared light. The problem with current radiation therapy is that in most cases it is not confined to malignant growths and healthy tissue gets caught in the crossfire, according to von Maltzahn.

His other award-winning technique involves two injections: The first batch are sent out as scouts to identify and attach to tumors. Once in place, they serve as markers for a second battalion of nanoparticles that are covered with cancer-fighting agents, which home in on and destroy the tumors but leave healthy tissue unscathed. In mouse trials, von Maltzahn and his colleagues found that this "scout–assassin" system successfully delivered doses of medicine in mice that were more than 40-times more potent and much more successful at killing tumors than were injected medicine-coated particles sans the ability to communicate with nanoparticle advance teams.

The major benefit of both von Maltzahn's methods is that the medication could be injected anywhere in the body but would only latch onto the cancerous tissue. "If we were injecting this directly into the tumor, it wouldn't be a transformative technology," he says. "It's essential to be able to inject it intravenously anywhere in the body and have it … home in on the tumor." Once the medicine has been delivered, the nanoparticles would be stripped bare and could safely pass out of the body after being filtered from the blood by the spleen or liver, von Maltzahn says, noting that gold has a very low toxicity profile.



5 Comments

Add Comment
View
  1. 1. JamesDavis 03:24 PM 3/3/09

    I just knew getting Geoffrey those lego building blocks when he was three would pay off one day!!! Great going son!!! You are an honor to the human race. We need about 100,000 more wonderful people like you. Keep in touch and let us know all the other wonderful things you will be doing. Boy, we are really proud of you.

    Reply | Report Abuse | Link to this
  2. 2. choppam 06:25 AM 3/5/09

    Trillions of nanoparticles!!

    A golden opportunity.

    A fiery sword of light!

    Homing smidgeons!

    Hi-Tech maggots! (Devouring your dead meat, sparing your living flesh)

    Can't wait to see the headlines when this achieves therapy status!


    Reply | Report Abuse | Link to this
  3. 3. GarrettQ 10:48 PM 3/7/09

    Wonderful article/discovery.

    I do believe the expression is "hone in".
    "It's essential to be able to inject it intravenously anywhere in the body and have it & home in on the tumor."
    Maybe a typo by the writer?

    Reply | Report Abuse | Link to this
  4. 4. JockMcD 08:25 PM 4/7/09

    No, The correct usage is home in, as in homing pigeon, not as in hone a knife to a sharp edge. Wonderful article, inspirational and hopeful. And to think this guy did it all without government bailout money. The entrepreneur lives!!

    Reply | Report Abuse | Link to this
  5. 5. Hamilton 03:40 AM 3/9/10

    It looks wonderful Geoffrey.
    Do you think it will be effective against tumours in the head?
    I have a benigne meningeoma, which you probably know is a tumour on the meninge, or lining inside the skull, so it is not in the brain.
    I understand though, that there is something called a blood/brain barrier, which stops a lot of things getting through.
    Do the nanno bits get through that barrier?
    Best wishes.
    Hamilton in Australia

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Preying On a Tumor's Weakness with Nanotechnology to Fight Cancer

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X